RC48, a novel ADC with cleavable linker, showed promising antitumor activity in several types of HER2-positive tumors.23 We hypothesized that the bystander effect of T-Dxd and RC48 might overcome some of the drug resistance to achieve tumor response, but this strategy needs more evidence in the future. The gene discussed is ERBB2; the disease is neoplasm.